The biotech bi-weekly: partnerships facilitating antibody discovery and AI drug development

Mechanistic infrastructure for antibody discovery

Jazz Pharmaceuticals (Dublin) and AbCellera (Vancouver) entered a preclinical research collaboration, option, and license agreement to discover and develop next-generation T-cell engaging multispecific antibodies targeting gastrointestinal cancers and other solid tumors — indications whose incidence rises steeply with chronological age. FairJourney Bio (Porto) licensed AbTherx's Atlas™ Full Human Diversity and Common Light Chain mouse platforms, bringing transgenic antibody discovery fully in-house. In parallel, Gandeeva Therapeutics (Burnaby) and Zymeworks (Vancouver) announced a high-resolution cryo-EM effort to visualize antibody–antigen interfaces — the molecular layer that governs binding efficacy and downstream signaling.

AI-guided biologics and CNS-penetrant candidates

Harbour BioMed (Shanghai) and BioMap (CA, USA) committed to a multi-year strategic partnership around AI foundation models for complex biologics. Separately, BioTechniques reports a new machine-learning model that predicts how candidate molecules modulate gene expression, with early application to two indications described as "tough-to-treat." ChemDiv (CA, USA) disclosed preclinical and clinical milestones from its CNS-focused discovery platform, which supports the design of brain-penetrant small molecules — a narrow mechanistic category, and a direct constraint on neurodegeneration pipelines.

Gene-editing partnerships and BIO 2026 context

Gulf News reports that Abu Dhabi's Department of Health, M42, and Mammoth Biosciences — co-founded by Jennifer Doudna — signed an MoU at BIO International Convention 2026 in San Diego. The agreement covers CRISPR-based gene-editing for rare and inherited diseases, anchored by Mammoth's lead clinical candidate MB-111, lipid nanoparticle manufacturing, and integration with the Emirati Genome Programme and the HELM Cluster. PR Newswire confirms a Taiwan biotech delegation is also attending BIO 2026 to advance global partnerships, though specific agreement details were not disclosed in the public release.

What to track

We observe in the data a structural shift: antibody-discovery infrastructure is consolidating around integrated platforms — transgenic mice, cryo-EM visualization, AI-guided biologics design — rather than single-asset bets. The practical signal for longevity readers is not the announcement itself but the timeline. Multispecific antibodies, brain-penetrant small molecules, and CRISPR-based correction programs all share the same bottleneck: preclinical efficacy translating into validated human biomarkers.

The evidence base remains early. No efficacy data, cohort outcomes, or dosing schedules have been disclosed in the current round of announcements. We recommend monitoring peer-reviewed output from each partner over the next 12–24 months, with particular attention to phase I readouts for the Jazz/AbCellera solid tumor program, ChemDiv's CNS candidates, and Mammoth's MB-111 trajectory within the Abu Dhabi framework.